Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Keeping Track: UCB’s Very Good Day, Pfizer’s Great Year

Executive Summary

Pfizer adds Velsipity and Penbraya to its US FDA novel approval haul and UCB’s Bimzelx finally achieves FDA clearance, along with Zilbrysq.

You may also be interested in...

Pfizer’s Pentavalent Meningococcal Vaccine Gets CDC Cmte. Recommendation For Off-Label Use

The unusual move may be temporary as CDC plans to spend the next year working to revise the adolescent schedule for meningococcal vaccines. Pfizer indicated the decision might lead to a price shift for the recently approved Penbraya.

UCB Wins Two Key US Approvals: Bimzelx In Psoriasis, Zilbrysq In gMG

Two years after its first FDA review, UCB’s next blockbuster Bimzelx finally crossed the finish line. Supplemental filings for more indications will soon follow as the company forecasts €4bn in peak sales.

Pfizer Gets First Approval Of Arena’s Etrasimod, In Ulcerative Colitis

Branded as Velsipity, the S1P modulator will compete directly against classmate Zeposia in UC and faces a crowded field of anti-TNFs and other types of therapy. Pfizer paid $6.7bn for Arena in 2021.


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts